ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$0.22 USD
-0.04 (-14.84%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $0.21 -0.01 (-4.20%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NDRA 0.22 -0.04(-14.84%)
Will NDRA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NDRA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NDRA
Endra Life Sciences issued new European patent
Endra Life Sciences issued new European patent
ENDRA Life Sciences Inc trading halted, news pending
ENDRA Life Sciences Inc trading halted, news pending
12 Health Care Stocks Moving In Thursday's Pre-Market Session